Acute renal failure with the combined use of rosuvastatin and fenofibrate

Renal Failure

Volumn 32, Issue 5, 2010, Pages 633-635

  Buyukhatipoglu, Hakan ^a   Sezen, Yusuf ^a   Guntekin, Unal ^a   Kirhan, Idris ^a   Dag, Omer Faruk ^a  

^a HARRAN UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Acute renal failure; Fenofibrate; Rhabdomyolysis; Rosuvastatin

Indexed keywords

FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; PRAVASTATIN; RAMIPRIL; ROSUVASTATIN; TRIACYLGLYCEROL;

ACUTE KIDNEY FAILURE; ADULT; ANGIOGRAPHY; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY OBSTRUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEMATURIA; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LIPID ANALYSIS; MUSCLE WEAKNESS; NAUSEA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEINURIA; RHABDOMYOLYSIS; THORAX PAIN; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; URINALYSIS; VOMITING;

ADULT; ANTILIPEMIC AGENTS; DRUG INTERACTIONS; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, ACUTE; PROCETOFEN; PYRIMIDINES; SULFONAMIDES;

EID: 77952971115     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/08860221003759452     Document Type: Article

References (14)

1. Lloyd-Jones DM, O'Donnell CJ, D'Agostino RB, Massaro J, Silbershatz H, Wilson PW. Applicability of cholesterollowering primary prevention trials to a general population: The Framingham Heart Study. Arch Intern Med. 2001;161:949.
2. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: A systematic overview of randomized clinical trials. Circulation. 2006;114:2788.
3. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study) : Randomized controlled trial. Lancet. 2005;366:1849-1861.
4. Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol. 2006;97:69C.
5. Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med. 2006;119:400.
6. Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med. 995;333:664.
7. Knopp RN. Drug treatment of lipid disorders. N Engl J Med. 1999;341:498.
8. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 1988;319:24.
9. Oldemeyer JB, Lund RJ, Koch M, et al. Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations. Cardiology. 2000;94:127-128.
10. Unal A, Torun E, Sipahioglu MH, et al. Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients. Intern Med. 2008;47:1017-1019.
11. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292:2585-2590.
12. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Eng J Med. 2008;359:2195-2207.
13. Drug interactions with simvastatin. Med Lett Drugs Ther. 2008;50:83-84.
14. Ireland JH, Eggert CH, Arendt CJ, Williams AW. Rhabdomyolysis with cardiac involvement and acute renal failure in a patient taking rosuvastatin and fenofibrate. Ann Intern Med. 2005;142:949-950.